New targeted research could offer alternative treatment for Acute Myeloid Leukaemia Posted on July 18, 2014February 25, 2018 by Carly du Toit ACRF-funded research teams across Australia have collaborated to develop a remarkable new treatment option for Acute Myeloid Leukaemia (AML) and accelerate it into clinical trials. AML is a particularly aggressive form of cancer with poor survival rates; although chemotherapy can induce remission there is often a high chance of relapse. However, this new research, published in major international journal Cell Reports, details how a newly developed therapeutic antibody (CSL362) binds to the cancer cells and then recruits the body’s immune system to kill the cancer cells. Continue reading “New targeted research could offer alternative treatment for Acute Myeloid Leukaemia”
